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Abstract
There is a range of pharmacological options available to the rheumatologist for treating arthritis.
Non-selective NSAIDs or Cox-2 selective inhibitors are widely prescribed to reduce inflammation and
alleviate pain; however, they must be used with caution in individuals with an increased cardiovascular,
renal or gastrointestinal (GI) risk. The potential cardiovascular risks of Cox-2 selective inhibitors came to
light over a decade ago. The conflicting nature of the study data reflects some context dependency, but
the evidence shows a varying degree of cardiovascular risk with both Cox-2 selective inhibitors and
non-selective NSAIDs. This risk appears to be dose dependent, which may have important ramifications
for arthritis patients who require long-term treatment with high doses of anti-inflammatory drugs. The
renal effects of non-selective NSAIDs have been well characterized. An increased risk of adverse renal
events was found with rofecoxib but not celecoxib, suggesting that this is not a class effect of Cox-2
selective inhibitors. Upper GI effects of non-selective NSAID treatment, ranging from abdominal pain
to ulceration and bleeding are extensively documented. Concomitant prescription of a proton pump
inhibitor can help in the upper GI tract, but probably not in the lower. Evidence suggests that Cox-2
selective inhibitors are better tolerated in the entire GI tract. More evidence is required, and a composite
end-point is being evaluated. Appropriate treatment strategies are needed depending on the level of upper
and lower GI risk. Rheumatologists must be vigilant in assessing benefitrisk when prescribing a Cox-2
selective inhibitor or non-selective NSAID and should choose appropriate agents for each individual
patient.
Key words: Gastrointestinal bleeding, Cox-2 selective inhibitors, NSAID, Celecoxib, Diclofenac, Ibuprofen,
Cardiovascular risk, Renal risk, Ulcers, Proton pump inhibitors.
Introduction
Patients suffering from RA or OA require a combination of
non-pharmacological and pharmacological treatment
modalities to manage their condition.
As physicians, our aim is to control pain, optimize func-
tion and modify the disease process as much as we are
able to. In RA, we aim to stop disease progression as well
as reducing pain and maintaining functionality. In OA,
although there is, as yet, no treatment to halt the pro-
cesses of degeneration and inflammation, we can aim to
reduce joint pain and inflammation while improving and
maintaining joint function. We have a range of options
at our disposal to help us achieve these goals: ranging
from exercise and weight loss to oral analgesics, IA thera-
pies, DMARDs, including the biologicals and surgery.
When we meet an individual who is experiencing pain
and loss of function due to arthritis, gastrointestinal (GI)
care may not always be at the forefront of our minds. Yet,
it is an important element to take into consideration in
those patients to whom we prescribe treatment with
NSAIDs including both non-selective NSAIDs and Cox-2
selective inhibitors.
As rheumatologists, we are constantly making deci-
sions about which of these options represents the best
treatment for an individual with arthritis. We have many
factors to consider. To choose the most beneficial man-
agement option, we need to take into account comorbid
disorders in the patient and constitutional factors such as
obesity. The choice of treatment is affected by suitability,
availability, practicality, safety and costs.
In this article, the benefitrisk associated with non-
selective NSAIDs and Cox-2 selective inhibitors is
reviewed and the balance between GI and other risks
associated with these treatments is examined.
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Both non-selective NSAIDs and the newer Cox-2 selective
inhibitors are widely prescribed because of their proven
ability to reduce inflammation and control pain, and thus
optimize function. They are significantly more effective
than acetaminophen in terms of managing pain and thus
improving quality of life [1].
The EULAR guidelines of 2003 for OA in the knee rec-
ommend that NSAIDs are used if up to 41000mg/day
paracetamol (acetaminophen) is ineffective, moving to
opioid analgesics (e.g. codeine and tramadol) with or with-
out acetaminophen if NSAIDs prove ineffective [2].
Guidelines for RA similarly recommend the use of non-
selective NSAIDs/Cox-2 selective inhibitors [35], as do
the 2008 guidelines for OA from the National Institute for
Health and Clinical Excellence in the UK [6].
Guidelines, of course, remind us that these treatments
should be used with caution in individuals who may be at
increased cardiovascular, renal and GI risk. This article
reviews the evidence that rheumatologists may use in
assessing GI risk in the context of the other risks in indi-
viduals with arthritis who are taking non-selective NSAID
or Cox-2 selective treatments in order to maximize benefit
for the patient.
Despite these risks, NSAIDs play a key role in the
management of arthritis conditions. That they are more
effective than placebo has been shown by several clinical
trials. In one randomized control trial, which compared
both celecoxib and diclofenac with placebo in 600
patients over a period of 6 weeks, it was shown that
both the non-selective NSAID and the Cox-2 selective
inhibitor were better than placebo in managing pain [7]
(Fig. 1).
Cardiovascular risk: the evidence
There has been much debate and analysis of cardiovas-
cular risk associated with the use of Cox-2 selective
inhibitors and non-selective NSAIDs in the past decade.
The Vioxx Gastrointestinal Outcomes Research (VIGOR)
trial [8] and the Adenomatous Polyp Prevention on Vioxx
(APPROVe) trial [9] both showed an increase in cardiovas-
cular risk with rofecoxib (50 and 25mg/day, respectively)
compared with naproxen (500mg/day) or placebo,
respectively. Rofecoxib was then voluntarily withdrawn
from the market by the company. A whole range of con-
current studies looking at other Cox-2 selective inhibitors
and non-selective NSAIDs also found increases in cardio-
vascular risk.
The Adenoma Prevention with Celecoxib (APC) trial
showed a dose-related increase in the composite
end-point of cardiovascular death, myocardial infarction
(MI) or stroke with celecoxib compared with placebo
over 3 years of treatment [10]. The objective of this trial
was to test the efficacy and safety of celecoxib compared
with placebo in reducing colorectal adenoma recurrence
after polypectomy. The participants received either
200mg celecoxib twice daily (bid) (n=685), 400mg bid
(n=671) or placebo (n=679). In this long-term trial, a
safety committee adjudicated and categorized serious
cardiovascular events. Of the participants, 77% were fol-
lowed up for 37 months for adjudicated cardiovascular
events. The hazard ratio (HR) for the composite end-point
was 2.3 (95% CI 0.9, 5.5) in patients taking 200mg bid
and 3.4 (95% CI 1.5, 7.9) in patients taking 400mg bid.
There were also significant rises in systolic blood pressure
levels in both dose groups at 1 and 3 years. These were as
follows: 200mg bid: 1 year, 2.0mmHg; 3 years,
2.6mmHg; 400mg bid: 1 year, 2.9mmHg; 3 years,
5.2mmHg.
However, there are conflicting data reported in the lit-
erature: in a national casecontrol study from Finland,
Helin-Salmivaara et al. [11] set out to evaluate the risk of
Erst MI associated with the use of NSAIDs in the general
population. Over 33000 patients with Erst-time MI were
identiEed and the authors found an increased risk of
first-time MI with rofecoxib and etoricoxib but not cele-
coxib. They also found an increased risk with diclofenac,
indomethacin, ibuprofen and naproxen.
Fig. 1 Mean change in patients’ assessment of pain (measured on visual analogue scale) following treatment for 6 weeks
with celecoxib 100mg bid, diclofenac 50mg tid or placebo [6]. *change significantly better than placebo (P<0.001).
Adapted from McKenna et al. [7].
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that they too may be associated with cardiovascular (CV)
risk. McGettigan and Henry [12] conducted a systematic
review of observational studies in which they examined
cardiovascular (primarily MI) risk of Cox-2 selective inhib-
itors and non-selective NSAIDs. They looked at 17
patientcontrol and six cohort studies in a total of nearly
1 million patients, and found that CV risk was increased
with rofecoxib as well as with diclofenac, indomethacin
and probably meloxicam. Rofecoxib risk was increased
at low and high doses, and was evident during the first
30 days of use as well as with long-term treatment. Their
analysis showed that there was neither increased nor
decreased risk with naproxen, which had previously
been thought to be cardioprotective. Although the relative
risk (RR) for ibuprofen was not statistically significantly
increased compared with that for naproxen, the lower
bound of its 95% CI approached 1 (RR 1.07; 95% CI
0.97, 1.18), which suggests a level of risk (Table 1). In the
review, celecoxib showed an increased risk at a dose
>200mg/day, while risk at 200mg/day was not increased.
At the same time, another meta-analysis looked at dif-
ferences in cardiovascular outcomes between rando-
mized clinical trials in non-selective NSAIDs and Cox-2
selective inhibitors. This analysis also found similar
increased risks in cardiac events between these agents
(with the exception of naproxen), though there was some
suggestion that Cox-2 selective inhibitors actually had
more heterogeneity in cardiovascular risk than the
non-selective NSAIDs [13].
Further evidence that both non-selective NSAIDs and
Cox-2 selective inhibitors are associated with an
increased risk of cardiovascular events comes from a
study of 107092 patients with chronic heart failure, of
whom approximately one-third had a history of NSAID
use [14]. The HRs for death in patients using specific
NSAIDs ranged from 1.22 (95% CI 1.07, 1.39) with
naproxen (all doses) to 2.08 (95% CI 1.95, 2.21) with
high-dose diclofenac (Fig. 2). With celecoxib (all doses),
the HR was 1.75 (95% CI 1.63, 1.88). NSAID use was also
associated with dose-dependent increases in the risk of
death or hospitalization for MI or heart failure.
Although studies such as these have consistently
demonstrated an increased cardiovascular risk asso-
ciated with NSAID use, the issue remains complex.
One recent study suggests that in certain situations,
NSAIDs are not associated with an increased risk, and
could even be cardioprotective. In this small study of 923
Fig. 2 HRs and 95% CIs for the risk of death associated with NSAID use in patients with chronic heart failure. Adapted
with permission from Gislason et al. [14]. Copyright ! 2009 American Medical Association. All rights reserved.
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Table 1 RR of cardiovascular events with Cox-2 selec-
tive inhibitors and non-selective NSAIDs in a systematic
review of 17 patientcontrol and six cohort studies [11]
RR (95% CI)
Cox-2
Celecoxib 1.06 (0.91, 1.23)
Meloxicam 1.25 (1.00, 1.55)
Rofecoxib 1.35 (1.15, 1.59)
NSAID
Naproxen 0.97 (0.87, 1.07)
Piroxicam 1.06 (0.70, 1.59)
Ibuprofen 1.07 (0.97, 1.18)
Indometacin 1.30 (1.07, 1.60)
Diclofenac 1.40 (1.16, 1.70)
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associated with a reduced risk of cardiovascular mortality
[adjusted odds ratio (OR) 0.54; 95% CI 0.34, 0.86] [15].
However, these findings in a general practitioner popula-
tion might be subject to confounding, e.g. by a tendency to
avoid NSAID use in frail patients with existing cardiovas-
cular disease [15].
In summary, emerging evidence shows that both
non-selective NSAIDs and Cox-2 selective inhibitors are
associated with varying degrees of cardiovascular risk.
This risk appears to be dose dependent, and this may
have important implications for patients who require
long-term treatment with high doses of NSAIDs for OA
or RA.
Renal risk
Both non-selective NSAIDs and Cox-2 selective inhibitors
are associated with nephrotoxicity [16], which can
range from fluid and electrolyte disturbances to overt
renal dysfunction, renal papillary necrosis or nephrotic
syndrome [17]. As a result, current guidelines recommend
that NSAIDs should not be used in patients with severe
renal insufficiency, and that caution is necessary in
patients with hypertension, congestive heart failure,
mild-to-moderate renal insufficiency or other conditions
associated with decreased intravascular volume oedema
[3, 16].
Although the renal adverse effects of non-selective
NSAIDs have been well characterized, the risk associated
with Cox-2 selective inhibitors is less well documented.
Zhang et al. [18] investigated the RRs of renal adverse
events associated with rofecoxib or celecoxib in a
meta-analysis of 114 clinical trials, involving 116094
patients, of whom 6394 (5.5%) had peripheral oedema,
hypertension or renal dysfunction. The RRs for renal dys-
function or peripheral oedema in patients treated with
rofecoxib were 2.31 (95% CI 1.05, 5.07) and 1.43 (95%
CI 1.23, 1.66), respectively; in contrast, celecoxib was
associated with a lower risk of renal adverse events,
with RRs for renal dysfunction and peripheral oedema of
0.61 (95% CI 0.40, 0.94) and 1.09 (95% CI 0.91, 1.31),
respectively [18]. The risk of renal adverse events asso-
ciated with rofecoxib increased with both dose and
duration of treatment. These findings suggest that there
does not appear to be a class effect in terms of renal
adverse events with Cox-2 selective inhibitors [18]. The
same caution is needed for all non-selective NSAIDs as
well as for all Cox-2 selective inhibitors.
GI risks
GI damage associated with NSAIDS has been extensively
documented. Upper GI problems such as asymptomatic
mucosal damage, abdominal pain or dyspepsia, and seri-
ous complications such as ulcers or bleeding are common
findings in patients treated with NSAIDs [19]; endoscopic
lesions have been reported to be present in 24% of
patients [20], and up to 4% of patients each year experi-
ence complications [21]. Risk factors for NSAID-related
upper GI bleeding include high-dose NSAID treatment,
longer duration of treatment, increasing age and a previ-
ous history of peptic ulcer [22].
Studies have consistently shown that Cox-2 selective
inhibitors offer a more favourable GI toxicity profile than
non-selective NSAIDs. For example, in the Multinational
Etoricoxib and Diclofenac Arthritis Long-term (MEDAL)
study [23], which involved over 34000 patients with OA
or RA who were treated for up to 3.5 years, the incidence
of upper GI adverse events was significantly lower
with etoricoxib (60 or 90mg/day) than with diclofenac
(150mg/day) (HR 0.69; 95% CI 0.57, 0.83; P=0.0001).
Overall in the study, there were more lower GI events
than upper GI events (Fig. 3). Similarly, in the Celecoxib
Long-term Arthritis Safety Study (CLASS), a randomized
controlled trial involving 8059 patients with OA or RA, the
combined annualized incidence of upper GI ulcer com-
plications was significantly lower in patients receiving
celecoxib than in those receiving diclofenac or ibuprofen
(0.44 vs 1.27%, P=0.04) in patients not taking aspirin [24].
This risk reduction was also seen in the SUccessive
Celecoxib Efficacy and Safety Study-1 (SUCCESS-1),
which compared celecoxib with diclofenac or naproxen
in a double-blind controlled trial involving 13274 patients
(OR 7.02; 95% CI 1.46, 33.80; P=0.008) [25]. The reduc-
tion in risk with celecoxib in both CLASS and SUCCESS-1
was confounded by the inclusion of patients taking con-
comitant ASA; this is consistent with the finding that even
low doses of ASA used for prophylaxis of vascular events
are associated with an increased risk of peptic ulcer
bleeding [26].
The findings of individual studies such as these are
reinforced by a systematic review of randomized con-
trolled trials comparing Cox-2 selective inhibitors with
either non-selective NSAIDs or placebo [27]. This analysis
showed that Cox-2 selective inhibitors were associated
with significantly lower risks of gastroduodenal ulcer (RR
0.26; 95% CI 0.23, 0.30) and clinically important ulcer
complications (RR 0.39; 95% CI 0.31, 0.50) than
non-selective NSAIDs.
Fig. 3 Cumulative incidence of upper and lower GI
events in 34701 OA and RA patients treated with
diclofenac or etoricoxib in the MEDAL Study [2].
Adapted from Laine et al. [23].
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to the upper GI tract. Potential adverse effects of these
agents in the lower bowel include mucosal inflamma-
tion and increased mucosal permeability, ulcerations,
strictures, perforation and bleeding [28]. In some cases,
the presenting sign may be anaemia due to occult
bleeding.
Although such problems have been poorly character-
ized, accumulating evidence shows that they may
account for a significant proportion of GI events in
NSAID users. In the MUCOSA trial, which evaluated the
impact of misoprostol treatment on upper GI events, lower
bowel events were actually more common than gastro-
duodenal events, being present in 147 and 95 patients,
respectively [29]. In a further study, 40% of all serious GI
adverse events were serious lower bowel complica-
tions such as obstruction, perforation or major bleeding
[30]. More recently, a systematic review has reported
that up to 71% of NSAID users have small mucosal
breaks or small intestine injury, and that up to 88% of
patients with lower GI bleeding were NSAID users [31].
Cox-2 selective inhibitors are associated with a smaller
risk of lower GI complications than non-selective
NSAIDs [31].
The importance of NSAID-related adverse events in the
lower GI tract is highlighted by recent data showing that
such events are associated with higher mortality, more
prolonged hospitalizations and greater demands on
health care resources than upper GI events [32]. The
impact of NSAID-related lower GI events is likely to
become an increasing clinical concern because the avail-
able evidence indicates that these adverse events are
becoming more common as the incidence of upper GI
events diminishes [32].
Implications for the choice of treatment
Clearly, NSAIDs can be associated with cardiovascular,
renal and GI risks. How, then, might the benefits of
NSAID therapy best be balanced against these risks?
Appropriate treatment strategies for patients at different
levels of GI or cardiovascular risk are summarized in Fig. 4
[33]. In patients at risk of GI adverse events, with low or
moderate cardiovascular risk, either a combination of a
non-selective NSAID and a proton pump inhibitor, or a
Cox-2 selective inhibitor is appropriate. The available evi-
dence indicates that these two strategies have equivalent
GI safety profiles [35], although there have been relatively
few direct comparisons [34]. In patients at highest risk of
GI events, but low or moderate cardiovascular risk, a
combination of a Cox-2 selective inhibitor and a proton
pump inhibitor may be considered. Evidence to support
this approach comes from a randomized, double-blind
study in which the incidence of recurrent bleeding
was significantly lower in (Helicobacter pylori-negative)
patients receiving celecoxib 200mg bid. plus esomepra-
zole 20mg bid than in those receiving celecoxib alone
[35]. In view of the increased risk of cardiovascular
events associated with some Cox-2 selective inhibitors
and non-selective NSAIDs, these agents should be used
very cautiously in patients at high cardiovascular risk.
In patients at high cardiovascular risk who are at moder-
ate risk of GI adverse events, the combination of a non-
selective NSAID and a proton pump inhibitor may be
appropriate; in patients with both high cardiovascular
risk and high GI risk NSAIDs should be avoided comple-
tely if possible.
While the use of a proton pump inhibitor may reduce the
risks of NSAID-related upper GI adverse events, this strat-
egy is unlikely to have any impact on the risk of lower GI
events [31]. In view of the increased recognition of the
latter events [32], and the evidence that the risk of such
events is lower with Cox-2 selective inhibitors than with
non-selective NSAIDs [31], there is a case for the use of
Cox-2 selective inhibitors in preference to non-selective
NSAIDs in patients at risk of lower GI events. However,
this raises the question of how such patients can be iden-
tified; as noted above, the presence of anaemia may be a
key factor in identifying lower GI bleeding in NSAID-
treated patients. The introduction of a novel end-point
named Clinically Significant Upper and/or Lower GI
Events (CSULGIEs) captures adverse events throughout
the entire length of the GI tract, and may provide impor-
tant information on the NSAID-related risk of lower GI
events.
Conclusions
NSAIDs remain an essential option for treating inflamma-
tion and pain, but clearly, as clinicians we should aim
to minimize NSAID-related risks wherever possible.
This may involve the use of a Cox-2 selective inhibitor,
alone or with gastroprotective therapy, and the choice
of an agent with a low risk of renal or cardiovascular
adverse effects. We should be vigilant in identifying our
patients’ risks of adverse events, and in monitoring such
risks, use all available data to improve outcomes for our
patients.
Fig. 4 Strategies to decrease cardiovascular and GI
adverse events with NSAIDs or Cox-2 selective inhibitors.
aAmerican Heart Association Guidelines define patients at
risk of CV events as 10-year risk of CV event 10% [36].
bHigh risk indicates patients with previous ulcer bleed
at estimated rate of UGI complications of >28.8 cases
per 100 patient years [37]. Adapted from Lanas et al. [32].
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. NSAIDs and Cox-2 selective inhibitors are asso-
ciated with cardiovascular, GI and renal risk.
. The level of risk varies according to drug and dose.
. Individual patient risk needs to be assessed when
prescribing anti-inflammatory treatments.
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